Nanjing Luye Pharmaceutical competitive analysis

Explore patent oppositions filed by Nanjing Luye Pharmaceutical against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
Injectable Suspensions Having Improved Injectability PropertiesALKERMES CONTROLLED THERAPEUTICSDec 16, 2016

Explore Nanjing Luye Pharmaceutical's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
Oct 7, 2020Risperidone Sustained Release Microsphere Composition1
Jul 17, 2019Risperidone Sustained Release Microsphere Composition2

Latest PTAB cases involving Nanjing Luye Pharmaceutical

Discover the latest PTAB cases involving Nanjing Luye Pharmaceutical, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Nanjing Luye Pharmaceutical with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
NANJING LUYE PHARMACEUTICAL13 - -
AERA25 - - -
ALKERMES CONTROLLED THERAPEUTICS - 5 - 2
ALKERMES PHARMA IRELAND61812